Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05167721 · ClinicalTrials.gov registry record · Phase 2
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
A Phase 2 study of Multiple System Atrophy, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT05167721: Active Phase 2 study of Multiple System Atrophy, sponsored by Mayo Clinic.
NCT05167721 is a Phase 2 study of Multiple System Atrophy that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 71 participants, below the 266-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05167721, a Phase 2 study of Multiple System Atrophy, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
Multiple system atrophy (MSA) is a rare, rapidly progressive, and invariably fatal neurological condition characterized by autonomic failure, parkinsonism, and/or ataxia. There is no available treatment to slow or halt disease progression. The purpose of this study is to assess optimal dosing frequency, effectiveness and safety of adipose-derived autologous mesenchymal stem cells delivered into the spinal fluid of patients with MSA. Funding source: FDA Office of Orphan Product Development (OOPD), Mayo Clinic Executive Dean for Research Transformational Award, Mayo Clinic Regenerative Medicine, and Mayo Clinic Department of Neurology.
Primary Outcome
Rate of disease progression assessed using the change in the UMSARS total (= UMSARS I + UMSARS II) score
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Autologous Mesenchymal Stem Cells
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT05167721 still lists
NCT05167721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 266-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Multiple System Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05167721 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05167721 about?
NCT05167721 is a clinical study titled "Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy". Multiple system atrophy (MSA) is a rare, rapidly progressive, and invariably fatal neurological condition characterized by autonomic failure, parkinsonism, and/or ataxia. There is no available treatment to slow or halt disease progression. The purpose of this study is to assess optimal dosing freque...
What is the current status of trial NCT05167721?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2021-12-15. Estimated completion is 2026-12.
What conditions does trial NCT05167721 study?
This clinical trial studies the following conditions: Multiple System Atrophy.
What interventions are being tested in trial NCT05167721?
The interventions under investigation include: Placebo (OTHER), Autologous Mesenchymal Stem Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05167721?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05167721 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple System Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05167721's enrollment target sits among peer trials
71 16th of 30 higher than 15 of 30 other Multiple System Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple System Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
RECRUITING · Phase 2
-
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
RECRUITING · Phase 2
-
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
RECRUITING · Phase 2
-
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
RECRUITING · Phase 2
-
A Study of Lu AF82422 in Participants With Multiple System Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI